Epidermal growth factor receptor gene mutations and clinicopathologic correlation in 309 patients with non-small cell lung cancer

Chinese Journal of Pathology

Volumn 40, Issue 10, 2011, Pages 660-663

  Feng, Qin ^a   Li, Xiang Hong ^b   Chen, Zhao ^b   He, Jing Sheng ^b   Wang, Chun Xu ^b   Zhou, Li Xin ^b   Xue, Wei Cheng ^b  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^b NONE

Author keywords

Carcinoma; Epidermal growth factor; Non small cell lung; Polymerase chain reaction; Receptor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ADENOCARCINOMA; ADENOSQUAMOUS CARCINOMA; ADULT; AGE; AGED; ARTICLE; EXON; FEMALE; GENETICS; HUMAN; LARGE CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; MIDDLE AGED; MUTATION; MUTATION RATE; PATHOLOGY; PROTO ONCOGENE; SEX DIFFERENCE; SMOKING; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; EXONS; FEMALE; GENES, ERBB-1; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; MUTATION RATE; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEX FACTORS; SMOKING;

EID: 80555128939     PISSN: 05295807     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0529-5807.2011.10.004     Document Type: Article

References (14)

1. Linardou H, Dahabreh IJ, Bafaloukos D, et al. Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. Nat Rev Clin Oncol, 2009,6(6) :352-366.
2. Herbst RS, Heymach JV,Lippman SM. Lung cancer. N Engl J Med, 2008,359(13): 1367-1380.
3. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib. N Engl J Med, 2004, 350 (21): 2129-2139. (Pubitemid 38637993)
4. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 2004, 304(5676): 1497-1500. (Pubitemid 38720929)
5. Rosell R, Moran T, Queratt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med, 2009, 361(10): 958-967.
6. Pao W,Miller V.Zakowski W, et al. EGF receptor gene mutations are common in lung cancers from " never smokers " and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A, 2004, 101(36): 13306-13311. (Pubitemid 39209661)
7. Horn L,Sandler A. Epidermal growth factor receptor inhibitors and antiangiogenic agents for the treatment of non-small cell lung cancer. Clin Cancer Res, 2009,15(16) : 5040-5048.
8. Pao W, Ladanyi M. Epidermal growth factor receptor mutation testing in lung cancer; searching for the ideal method. Clin Cancer Res, 2007,13(17): 4954-4955.
9. Endo K, Konishi A, Sasaki H, et al. Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay. Lung Cancer, 2005,50 (3) :375-384.
10. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancermolecular and clinical predictors of outcome. N Engl J Med, 2005,353(2) :33-144.
11. Sequist LV, Joshi VA, Jänne PA, el al. Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. Oncologist, 2007,12 (1) :90-98. (Pubitemid 46143506)
12. Shukuya T, Takahashi T, Kaira R, et al. Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports. Cancer Sci, 2011,102(5) : 1032-1037.
13. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med, 2008,358(11): 1160-1174.
14. Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci, 2007,98 (12) : 1817-1824. (Pubitemid 350002184)